Opthea Limited Completes Nasdaq Delisting

Opthea Limited Sponsored ADR ( (OPT) ) has issued an announcement.

On November 21, 2025, Opthea Limited announced the effective voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Global Select Market. This strategic move involves filing a Form 15F with the SEC to deregister and terminate its reporting obligations under the Securities Exchange Act of 1934. While Opthea’s ordinary shares will remain listed on the ASX, trading of its securities is currently suspended under ASX Listing Rule 17.3. Post-delisting, Opthea’s ADSs may be traded in the U.S. Over-The-Counter market, impacting its market presence and trading dynamics.

The most recent analyst rating on (OPT) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Opthea Limited Sponsored ADR stock, see the OPT Stock Forecast page.

Spark’s Take on OPT Stock

According to Spark, TipRanks’ AI Analyst, OPT is a Underperform.

Opthea Limited’s stock is currently rated low due to significant financial challenges, including persistent losses, high leverage, and poor cash flow management. The technical analysis indicates a bearish trend with no immediate recovery signals. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, suggesting limited appeal to investors seeking growth or income. The stock’s high beta adds to the risk profile, emphasizing the need for strategic improvements to enhance financial performance.

To see Spark’s full report on OPT stock, click here.

More about Opthea Limited Sponsored ADR

Opthea Limited is a biotechnology company focused on the development of therapies for eye diseases. The company is primarily engaged in creating treatments for retinal diseases and is listed on the Australian Securities Exchange (ASX).

Technical Sentiment Signal: Sell

Current Market Cap: $478.6M

Learn more about OPT stock on TipRanks’ Stock Analysis page.